Abstract
Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Keywords: HE4, gynecologic cancers, ovarian cancers, endometrial cancers, cancer recurrence, prognosis.
Graphical Abstract
Current Drug Targets
Title:Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Volume: 18 Issue: 10
Author(s): Jinping Li, Haibin Chen, John R. Curcuru, Sheena Patel, Taylor O. Johns, Dimple Patel, Hua Qian*Shi-wen Jiang*
Affiliation:
- Department of Obstetrics and Gynecology, the Taizhou People's Hospital, Taizhou 225300, Jiangsu,China
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China / Department of Biomedical Science, Mercer University School of Medicine, Savannah, Georgia 31404,United States
Keywords: HE4, gynecologic cancers, ovarian cancers, endometrial cancers, cancer recurrence, prognosis.
Abstract: Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Export Options
About this article
Cite this article as:
Li Jinping, Chen Haibin, Curcuru R. John, Patel Sheena, Johns O. Taylor, Patel Dimple, Qian Hua*, Jiang Shi-wen *, Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170404154929
DOI https://dx.doi.org/10.2174/1389450118666170404154929 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga
Current Pharmacogenomics and Personalized Medicine The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents MicroRNAs for Diagnosis and Treatment of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets SALL4: Engine of Cell Stemness
Current Gene Therapy Synthesis and Activity of Epothilone D
Current Drug Targets Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Modulation of Matrix Metalloproteinase Activity by Tobacco Cigarette Smoke
Current Chemical Biology Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy
Current Topics in Medicinal Chemistry A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design The Role of miRNAs in Plasma Cell Dyscrasias
MicroRNA Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Obesity and Cancer: Biological Links and Treatment Implications
Current Cancer Drug Targets Editorial [Hot Topic: The Therapeutic Potential of FOXO Proteins (Guest Editor: Wolfgang Link)]
Current Drug Targets Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry